SLC5A2 and type 2 diabetes mellitus: Given the efficacy of GLP-1R agonism and SGLT2 inhibition in CV prevention, there is a growing need for prospective outcome studies assessing the efficacy of simultaneous or sequential addition of both these drugs to T2DM management.